CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TBG Diagnostics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TBG Diagnostics Ltd
U 6 138 Juliette Street, Greenslopes
Phone: +61 730887926p:+61 730887926 BRISBANE, QLD  4120  Australia Fax: +61 733944394f:+61 733944394

This company is no longer actively traded on any major stock exchange.

Business Summary
TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202012/31/2020YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board Indrajit S.Arulampalam 5/17/2016 7/12/2013
Chief Executive Officer - Pharmasynth LeslieTillack
Chief Operating Officer WillyHsu 2/1/2019 2/1/2019
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Cellgate, Inc
PGLA
Progen Industries Limited
6 additional Business Names available in full report.

General Information
Number of Employees: 41 (As of 6/30/2005)
Outstanding Shares: 217,587,289 (As of 12/31/2020)
Shareholders: 2,014
Stock Exchange: ASX
Fax Number: +61 733944394


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023